Kazia Therapeutics

(NASDAQ) KZIA

Current Price$11.93

Market Cap$134.33M

Since IPO (1999)-100%

5 Year-98%

1 Year+233%

1 Month+66%

Kazia Therapeutics Financials at a Glance

Market Cap

$134.33M

Revenue (TTM)

$2.52M

Net Income (TTM)

$50.68M

EPS (TTM)

$-6.82

P/E Ratio

-1.74

Dividend

$0.00

Beta (Volatility)

1.03 (Average)

Dividend

$0.00

Beta (Volatility)

1.03 (Average)

Price

$11.93

Volume

Open

$12.00

Price

$11.93

Volume

Open

$12.00

Previous Close

$11.85

Daily Range

$11.37 - $12.58

52-Week Range

$3.05 - $17.40

Dividend

$0.00

Beta (Volatility)

1.03 (Average)

Price

$11.93

Volume

Open

$12.00

Previous Close

$11.85

Daily Range

$11.37 - $12.58

52-Week Range

$3.05 - $17.40

KZIA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Kazia Therapeutics

Industry

Biotechnology

Sector

Health Care

CEO

John E. Friend, II, MD

Website

www.kaziatherapeutics.com

Headquarters

Sydney, NSW 2000, AU

KZIA Financials

Key Financial Metrics (TTM)

Gross Margin

100%

Operating Margin

-921%

Net Income Margin

-1130%

Return on Equity

-103%

Return on Capital

-39%

Return on Assets

-31%

Earnings Yield

-57.47%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$134.33M

Shares Outstanding

11.34M

Volume

Avg. Volume

205.07K

Financials (TTM)

Gross Profit

$42.00K

Operating Income

$14.22M

EBITDA

$13.28M

Operating Cash Flow

$13.28M

Capital Expenditure

$0.00

Free Cash Flow

$13.28M

Cash & ST Invst.

$4.34M

Total Debt

$396.00K

Kazia Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

$134.33M

N/A

Market Cap/Employee

$14.93M

N/A

Employees

N/A

Net Income

$12.32M

-39.7%

EBITDA

$13.30M

-67.3%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Net Cash

$69.29M

+2063.2%

Accounts Receivable

$315.23K

+382.0%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$98.71K

-72.5%

Return on Assets

-31.35%

N/A

Return on Invested Capital

-38.87%

N/A

Free Cash Flow

$9.07M

-43.2%

Operating Cash Flow

$9.07M

-43.2%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

SNGXSoligenix, Inc.

SNGXSoligenix, Inc.$0.42-70.25%

SILOSilo Pharma, Inc.

SILOSilo Pharma, Inc.$0.44+1.32%

TTNPTitan Pharmaceuticals, Inc.

TTNPTitan Pharmaceuticals, Inc.$2.34-11.36%

OGENOragenics, Inc.

OGENOragenics, Inc.$0.61-3.87%

CANFCan-Fite BioPharma Ltd.

CANFCan-Fite BioPharma Ltd.$2.91-0.34%

CNSPCNS Pharmaceuticals, Inc.

CNSPCNS Pharmaceuticals, Inc.$2.26-1.10%

INMInMed Pharmaceuticals Inc.

INMInMed Pharmaceuticals Inc.$0.70-4.31%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

NVDANvidia

NVDANvidia$213.48-0.01%

NOKNokia

NOKNokia$11.30+0.05%

AMZNAmazon

AMZNAmazon$259.79-0.01%

JOBYJoby Aviation

JOBYJoby Aviation$8.91-0.01%

AMDAdvanced Micro Devices

AMDAdvanced Micro Devices$323.61-0.03%

SQQQProShares Trust - ProShares UltraPro Short Qqq

SQQQProShares Trust - ProShares UltraPro Short Qqq$54.05+0.03%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$60.74-0.03%

Questions About KZIA

What is the current price of Kazia Therapeutics?

Kazia Therapeutics is trading at $11.85 per share.

What is the 52-week range for Kazia Therapeutics?

Over the past 52 weeks, Kazia Therapeutics has traded between $3.05 and $17.40.

How much debt does Kazia Therapeutics have?

As of the most recent reporting period, Kazia Therapeutics reported total debt of $259,518.6.

How much cash does Kazia Therapeutics have on hand?

Kazia Therapeutics reported $2.85M in cash and cash equivalents in its most recent financial results.

What is Kazia Therapeutics’s dividend yield?

Kazia Therapeutics does not currently have a dividend yield.

Kazia Therapeutics

Kazia Therapeutics Financials at a Glance

KZIA News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Kazia Therapeutics

KZIA Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Kazia Therapeutics Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About KZIA

What is the current price of Kazia Therapeutics?

What is the 52-week range for Kazia Therapeutics?

How much debt does Kazia Therapeutics have?

How much cash does Kazia Therapeutics have on hand?

What is Kazia Therapeutics’s dividend yield?

Premium Investing Services